Merck & Co., Inc.
General ticker "MRK" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $220.3B (TTM average)
Merck & Co., Inc. follows the US Stock Market performance with the rate: 14.0%.
Estimated limits based on current volatility of 1.6%: low 100.79$, high 103.97$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2025-09-15, amount 0.81$ (Y3.21%)
- Total employees count: 75000 as of 2024
- US accounted for 50.1% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Patent rights and exclusivity, Geopolitical risks, Climate change and natural disasters, Product development delays, Regulatory and compliance
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [84.89$, 123.36$]
- 2025-12-31 to 2026-12-31 estimated range: [89.27$, 128.42$]
Financial Metrics affecting the MRK estimates:
- Negative: with PPE of 13.0 at the end of fiscal year the price was very high
- Positive: Operating profit margin, % of 31.51 > 18.64
- Positive: 6.82 < Operating cash flow per share per price, % of 8.55
- Positive: Industry earnings per price (median), % of 5.67 > 4.43
- Positive: 18.93 < Shareholder equity ratio, % of 39.55 <= 41.86
- Positive: Return on assets ratio (scaled to [-100,100]) of 12.76 > 6.04
- Positive: Inventory ratio change, % of -0.87 <= -0.75
Short-term MRK quotes
Long-term MRK plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $59,283.00MM | $60,115.00MM | $64,168.00MM |
| Operating Expenses | $41,001.00MM | $57,161.00MM | $43,947.00MM |
| Operating Income | $18,282.00MM | $2,954.00MM | $20,221.00MM |
| Non-Operating Income | $-1,838.00MM | $-1,065.00MM | $-285.00MM |
| Interest Expense | $962.00MM | $1,146.00MM | $1,271.00MM |
| R&D Expense | $13,548.00MM | $30,531.00MM | $17,938.00MM |
| Income(Loss) | $16,444.00MM | $1,889.00MM | $19,936.00MM |
| Taxes | $1,918.00MM | $1,512.00MM | $2,803.00MM |
| Profit(Loss)* | $14,519.00MM | $365.00MM | $17,117.00MM |
| Stockholders Equity | $45,991.00MM | $37,581.00MM | $46,313.00MM |
| Inventory | $5,911.00MM | $6,358.00MM | $6,109.00MM |
| Assets | $109,160.00MM | $106,675.00MM | $117,106.00MM |
| Operating Cash Flow | $19,095.00MM | $13,006.00MM | $21,468.00MM |
| Capital expenditure | $4,388.00MM | $3,863.00MM | $3,372.00MM |
| Investing Cash Flow | $-4,960.00MM | $-14,083.00MM | $-7,734.00MM |
| Financing Cash Flow | $-9,119.00MM | $-4,810.00MM | $-7,032.00MM |
| Earnings Per Share** | $5.73 | $0.14 | $6.76 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.